Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crisugabalin in Central Neuropathic Pain
NCT06422117Phase 3Not yet recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- May 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in central neuropathic pain (CNP) comparing HSK16149 with Placebo (2 arms). Primary endpoint: Change in pain scores from baseline at 12 weeks. Planned start May 2024; status: not yet recruiting.
02
Drugs
crisugabalin besilate
03
Conditions
central neuropathic pain (CNP)
Beyond the preview
Go deeper on NCT06422117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422117.